Erbitux INN-cetuximab
In patients with metastatic colorectal cancer cetuximab is used in combination The European Medicines Agency has waived the obligation to submit the ...
erbitux epar product information en
Erbitux INN-cetuximab
Chaque mL de solution pour perfusion contient 5 mg de cetuximab. Chaque flacon de 20 mL contient européenne des médicaments http://www.ema.europa.eu/.
erbitux epar product information fr
Erbitux INN-cetuximab
Zwischen dem Ende der Cetuximab-Infusion und der Chemotherapie muss ein Arzneimittel-Agentur http://www.ema.europa.eu/ verfügbar.
erbitux epar product information de
Erbitux INN-cetuximab
21 nov. 2013 EMA/CHMP/701107/2013. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Erbitux. International non-proprietary name: ...
erbitux h c ii epar assessment report variation en
Erbitux INN-cetuximab
Ogni mL di soluzione per infusione contiene 5 mg di cetuximab. Ogni flaconcino da 20 mL contiene 100 mg di dei medicinali http://www.ema.europa.eu.
erbitux epar product information it
Erbitux INN-cetuximab
En pacientes con cáncer colorrectal metastásico cetuximab se utiliza en monoterapia o en Europea de Medicamentos http://www.ema.europa.eu/.
erbitux epar product information es
Erbitux INN-cetuximab
EMA/13275/2014. EMEA/H/C/000558. EPAR summary for the public. Erbitux cetuximab. This is a summary of the European public assessment report (EPAR) for
erbitux epar summary public en
Erbitux INN-Cetuximab
Subsequently the applicant restricted the indication for Erbitux to the combination treatment with irinotecan. The scientific discussion in this report focuses
erbitux epar scientific discussion en
Erbitux INN-cetuximab
21 nov. 2013 EMA/CHMP/701107/2013. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Erbitux. International non-proprietary name: ...
WC
Erbitux EPAR summary update II-62
EMA/775584/2013. EMEA/H/C/000558. Résumé EPAR à l'intention du public. Erbitux cetuximab. Ce document est un résumé du rapport européen public d'évaluation
erbitux epar summary public fr
- cetuximab ema approval
- cetuximab ema smpc
- cetuximab ema assessment report
- cetuximab ema label
- cetuximab ema report
- encorafenib cetuximab ema
- cetuximab spc ema
- cetuximab biosimilar ema